Cardioselective Infection With Coxsackievirus B3 Requires Intact Type I Interferon Signaling
- 6 February 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (5) , 756-761
- https://doi.org/10.1161/01.cir.103.5.756
Abstract
Background —Interferons (IFNs) play an important role in antiviral defense and have therapeutic potential in coxsackievirus heart disease. However, little is known about the relative contributions of type I and type II IFN signaling in coxsackievirus B3 (CVB3) infection or their role in the cardioselective nature of CVB3 infection. Methods and Results —Wild-type mice and mice deficient for either the type I or the type II IFN receptor (IFNR) were infected with CVB3. Infection of the type I IFNR–deficient mice with >10 3 plaque-forming units (pfu) of CVB3 resulted in 100% mortality within 2 to 4 days after infection. Death was rare in wild-type and type II IFNR–deficient mice after inoculation with as much as 10 8 pfu of CVB3. Surprisingly, the early mortality in the type I IFNR–deficient mice was not accompanied by higher virus titers in the heart. Unexpectedly, a dramatic increase of viral RNA in the liver was found to correlate with early mortality in type I IFNR–deficient mice. Conclusions —Type I but not type II IFN signaling is essential for the prevention of early death due to CVB3 infection. Interestingly, neither type I or type II IFN signaling has a dramatic effect on early viral replication in the heart. However, lethal viral replication in the liver is controlled by type I IFNs. These results demonstrate that the IFN system is capable of modulating both viral pathogenicity and tissue tropism.Keywords
This publication has 34 references indexed in Scilit:
- Fatao coxsackievirus B infection in early infancy characterized by fulminant hepatitisJournal of Infection, 1998
- Enterovirus‐induced myocarditis: Hemodynamic deterioration with immunosuppressive therapy and successful application of interferon‐αClinical Cardiology, 1994
- Functional Role of Type I and Type II Interferons in Antiviral DefenseScience, 1994
- Immune Response in Mice that Lack the Interferon-γ ReceptorScience, 1993
- Synergistic Interaction of Interferon- and Interferon- in Coxsackievirus B3-Infected Carrier Cultures of Human Myocardial FibroblastsThe Journal of Infectious Diseases, 1992
- Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in miceAmerican Heart Journal, 1988
- Constitutive expression of (2′–5′) oligo A synthetase confers resistance to picornavirus infectionNature, 1987
- Protective Effect of Interferon on Infections with Hand, Foot, and Mouth Disease Virus in Newborn MiceThe Journal of Infectious Diseases, 1986
- Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferonJournal of Molecular and Cellular Cardiology, 1985
- Virus interference. I. The interferonProceedings of the Royal Society of London. B. Biological Sciences, 1957